Taking the world by a storm in a wave of euphoria that even led to the stocks shooting up, Pfizer, in partnership with German BioNTech announced on Monday, that their mRNA-based covid vaccine candidate, BNT162b2, against coronavirus has demonstrated evidence of efficacy against COVID-19 in participants.
One of the most promising vaccine candidates jointly developed by Pfizer and BioNTech was 90 percent effective in preventing Covid-19 infections in ongoing Phase 3 trials, as of yesterday’s announcement. The statement sent European stock markets and oil prices shooting up, as global citizens felt relieved upon hearing the news.
Pfizer and BioNTech SE are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine. The companies said they have found no serious safety concerns so far, and expect to seek US emergency use authorization later this month.
The world’s entire population is waiting with bated breaths for a vaccine that would put an end to this ghastly pandemic once, and for all, and this reality might be a lot closer, even by the end of the year. In its statement, Pfizer said, “Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis,”
Pfizer chairman and CEO Albert Bourla stated, “Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19. We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We are reaching this critical milestone in our vaccine development program at a time when the world needs it most.”
Alongside the stack of data that has been collected from the final stages of the trial, Pfizer said both the companies are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced, for faster approval.
Thanking everyone who was a part of the trials, Bourla added, “I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor. We could not have come this far without the tremendous commitment of everyone involved.”
In July, Pfizer signed a contract to supply the US with 100 million doses for $1.95 billion, assuming the vaccine is cleared by the FDA. This vaccine, if administered by the end of the year, will be a revolutionary win for the incumbent Republican administration that is to be replaced by Joe Biden in January.